ATEA PHARMACEUTICALS INC (AVIR)
US04683R1068 - Common Stock
Overall AVIR gets a fundamental rating of 3 out of 10. We evaluated AVIR against 191 industry peers in the Pharmaceuticals industry. AVIR has a great financial health rating, but its profitability evaluates not so good. AVIR has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
AVIR had negative earnings in the past year.
AVIR had a negative operating cash flow in the past year.
AVIR had negative earnings in 4 of the past 5 years.
In the past 5 years AVIR reported 4 times negative operating cash flow.
1.2 Ratios
AVIR has a Return On Assets (-35.44%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -37.95%, AVIR is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.44% | ||
| ROE | -37.95% | ||
| ROIC | N/A |
ROA(3y)-8.18%
ROA(5y)-17.83%
ROE(3y)-8.5%
ROE(5y)-19.86%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for AVIR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, AVIR has about the same amount of shares outstanding.
Compared to 5 years ago, AVIR has more shares outstanding
AVIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.84 indicates that AVIR is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.84, AVIR is doing good in the industry, outperforming 78.80% of the companies in the same industry.
There is no outstanding debt for AVIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.84 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 19.33 indicates that AVIR has no problem at all paying its short term obligations.
With an excellent Current ratio value of 19.33, AVIR belongs to the best of the industry, outperforming 92.93% of the companies in the same industry.
AVIR has a Quick Ratio of 19.33. This indicates that AVIR is financially healthy and has no problem in meeting its short term obligations.
AVIR has a better Quick ratio (19.33) than 92.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.33 | ||
| Quick Ratio | 19.33 |
3. Growth
3.1 Past
AVIR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.01%.
EPS 1Y (TTM)-31.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 23.71% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.9%
EPS Next 2Y2.39%
EPS Next 3Y2.48%
EPS Next 5Y23.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
AVIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVIR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.39%
EPS Next 3Y2.48%
5. Dividend
5.1 Amount
AVIR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ATEA PHARMACEUTICALS INC
NASDAQ:AVIR (1/3/2025, 8:21:12 PM)
After market: 3.55 +0.03 (+0.85%)3.52
+0.1 (+2.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners69.8%
Inst Owner Change0.18%
Ins Owners2.74%
Ins Owner Change-12.89%
Market Cap297.30M
Analysts50
Price Target6.32 (79.55%)
Short Float %4.15%
Short Ratio9.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.6%
Min EPS beat(2)26.72%
Max EPS beat(2)38.49%
EPS beat(4)3
Avg EPS beat(4)12.81%
Min EPS beat(4)-21.2%
Max EPS beat(4)38.49%
EPS beat(8)7
Avg EPS beat(8)15.05%
EPS beat(12)11
Avg EPS beat(12)77.46%
EPS beat(16)14
Avg EPS beat(16)116.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-9.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)41.27%
EPS NY rev (1m)0%
EPS NY rev (3m)22.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.65 | ||
| P/tB | 0.65 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.07
EYN/A
EPS(NY)-1.56
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS0
BVpS5.43
TBVpS5.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.44% | ||
| ROE | -37.95% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-8.18%
ROA(5y)-17.83%
ROE(3y)-8.5%
ROE(5y)-19.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 19.33 | ||
| Quick Ratio | 19.33 | ||
| Altman-Z | 4.84 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.5%
EPS Next Y-21.9%
EPS Next 2Y2.39%
EPS Next 3Y2.48%
EPS Next 5Y23.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.61%
EBIT Next 3Y-3.75%
EBIT Next 5YN/A
FCF growth 1Y28.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.4%
OCF growth 3YN/A
OCF growth 5YN/A